摘要
目的:探讨瑞舒伐他汀钙片联合芪参益气滴丸治疗慢性心力衰竭的临床疗效、安全性及对患者心功能、炎症水平、氧化应激损伤的影响。方法:将2014年8月-2016年4月我院收治的90例慢性心力衰竭患者按随机数字表法分为观察组和对照组,各45例。对照组患者采用强心、利尿、扩血管等常规抗心力衰竭治疗,同时餐后0.5 h内口服芪参益气滴丸0.5 g,tid;观察组患者在对照组基础上睡前口服瑞舒伐他汀钙片20 mg,qd。比较两组患者治疗前后心功能、血清炎症因子、脑钠肽(BNP)、氧化应激水平,并观察两组患者临床疗效及不良反应发生情况。结果:治疗前,两组患者左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、BNP、超氧化物歧化酶(SOD)、血清髓过氧化酶(MPO)、基质金属蛋白酶9(MMP-9)水平比较,差异均无统计学意义(P>0.05);治疗后,两组患者LVEF显著升高,LVEDD、LVESD、TNF-α、IL-6、BNP显著降低,且观察组患者上述指标显著优于对照组,差异均有统计学意义(P<0.05);观察组患者MPO、MMP-9水平显著降低,SOD水平显著升高,且显著优于对照组,差异均有统计学意义(P<0.05);但对照组患者SOD、MPO、MMP-9水平与治疗前比较,差异无统计学意义(P>0.05)。观察组患者治疗的临床有效率为97.8%,显著高于对照组的82.2%,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:瑞舒伐他汀钙片联合芪参益气滴丸治疗慢性心力衰竭疗效显著,能有效降低患者炎症水平,减轻氧化应激损伤,延缓心室重构进程,改善心功能,且安全性较好。
OBJECTIVE： To investigate clinical efficacy and safety of Rosuvastatin calcium tablets combined with Qishen yiqi dripping pills in the treatment of chronic heart failure （CHF） and it effects on inflammatory level, oxidative stress injury and cardiac function of patients. METHODS： Ninety CHF patients in our hospital during Aug. 2014-Apr. 2016 were divided into observation group and control group according to random number table, with 45 cases in each group. Control group received routine anti-heart failure treatment as cardiac, diuretic, dilating vessel, and Qishen yiqi dripping pills orally 0.5 g, half an hour after meal, tid; observation group was additionally given Rosuvastatin calcium tablet orally 20 rag, at bedtime, qd, on the basis of control group. Cardiac function, serum inflammatory factor, BNP and oxidative stress levels were compared between 2 groups before and after treatment. Clinical efficacies and the occurrence of ADR were observed in 2 groups. RESULTS： Before treatment, there was no statisti- cal significance in LVEF, LVESD, LVEDD, TNF-α, IL-6, BNP, SOD, MPO and MMP-9 levels between 2 groups （P〉0.05）. After treatment, LVEF of 2 groups were increased significantly, while LVEDD, LVESD, TNF-α and IL-6, BNP levels were decreased significantly; the above indexes of observation group was significantly better than those of control group, with statistical significance （P〈0.05）. MPO and MMP-9 of observation group were significantly decreased, while SOD level was significantly increased and better than that of control group, with statistical significance （P〈0.05）, but there was no statistical significance in SOD and MPO, MMP-9 levels of control group before and after treatment （P〉0.05）. The clinical response rate of observation group was 97.8%, which was significantly higher than 82.2% of control group, with statistical significance （P〈0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P〉0.05）. CONCLUSIONS： Rosuvastatin c
出处
《中国药房》
CAS
北大核心
2017年第8期1098-1101,共4页
China Pharmacy
关键词
瑞舒伐他汀
芪参益气滴丸
慢性心力衰竭
心功能
炎症因子
氧化应激
Rosuvastatin
Qishen yiqi dripping pills
Chronic heart failure
Cardiac function
Inflammatory factor
Oxidative stress
